The meeting will go on as planned, minus Silva and Diaz.
Diaz is currently listed on the agenda for the March 23 meeting, but NAC executive director Bob Bennett told MMAWeekly.com on Thursday that Silva and Diaz each requested and was granted a continuance, meaning that both would likely go before the commission at its April meeting.
Silva and Diaz both face disciplinary hearings before the commission stemming from failed drug tests related to the UFC 183 headlining bout, which took place on Jan. 31 in Las Vegas.
Silva faces the commission following two failed drug tests. The first time he tested positive was in a Jan. 9 out-of-competition drug test, where his results revealed anabolic steroid metabolites for Drostanolone and Androstane.
After testing clean in a Jan. 19 out-of-competition test, Silva then again tested positive for Drostanolone, in addition to Oxazepam and Temazepam, two benzodiazepine class drugs commonly used to treat anxiety-related insomnia in his fight-night drug test.
Silva has never before tested positive for banned substances during his near-twenty-year career.
Diaz is required to go before the commission for testing positive for marijuana metabolites in his fight-night drug test.